Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05282836
Other study ID # HX-A-2021016
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 15, 2022
Est. completion date March 15, 2024

Study information

Verified date March 2022
Source Beijing Tiantan Hospital
Contact Runting Li
Phone +8615753166690
Email tt18080lrt@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a randomized, single-center trial. On the basis of standard-of-care, patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit. Patients in the control group received standard-of-care (consisting of oxygen therapy) alone. This study intends to apply Hydrogen/Oxygen Generator in clinical patients with aneurysmal subarachnoid hemorrhage (aSAH), exploring the role of hydrogen-oxygen mixed gas inhalation therapy in early brain injury, and the prevention of cerebral vasospasm and delayed cerebral ischemia, finally providing a scientific basis for hydrogen treatment of aSAH.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 206
Est. completion date March 15, 2024
Est. primary completion date March 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. Signed informed consent 3. Must be admitted within 72 hours after aneurysm rupture Exclusion Criteria: 1. physical disability caused by any reason before the onset of the disease 2. dementia or mental illness before the onset of the disease 3. more than 72 hours after aneurysm rupture admitted to hospital for treatment 4. do not cooperate with the treatment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Hydrogen Oxygen Generator with Nebulizer
Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary In- hospital Cerebral Vasospasm The proportion of patients with cerebral vasospasm at day 14 From baseline to 14 days
Primary In- hospital Delayed Cerebral Ischemia The proportion of patients with delayed cerebral ischemia at day 14 From baseline to 14 days
Secondary modified Rankin Scale score modified Rankin Scale score at 90 days after discharge 90 days after discharge
Secondary Montreal Cognitive Assessment score Montreal Cognitive Assessment score at 90 days after discharge 90 days after discharge
See also
  Status Clinical Trial Phase
Completed NCT03209830 - Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Not yet recruiting NCT03271697 - Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage Phase 2/Phase 3
Recruiting NCT01098890 - Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Active, not recruiting NCT05738083 - Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
Completed NCT03754335 - SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture N/A
Completed NCT06076590 - Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study Phase 4
Recruiting NCT04548401 - Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
Terminated NCT04148105 - Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 4
Recruiting NCT06329635 - Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial N/A
Recruiting NCT02129413 - Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm N/A
Terminated NCT00487461 - Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06288659 - aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial N/A
Recruiting NCT05974111 - COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
Recruiting NCT03706768 - Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06284642 - Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) Phase 4
Recruiting NCT01773200 - Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage N/A
Completed NCT02026596 - SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage N/A